Cbz-环己基-L-甘氨酸 | 69901-75-3

• 物质功能分类: 生物化工 - 氨基酸及其衍生物 - 甘氨酸类衍生物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: Cbz-环己基-L-甘氨酸
• 中文别名: N-苄氧羰基-环己基-L-甘氨酸；(S)-CBZ-环己基甘氨酸；CBZ-L-环己基甘氨酸；N-苄氧羰基-环；N-CBZ-L-环己基甘氨酸
• 英文名称: (S)-2-(((benzyloxy)carbonyl)amino)-2-cyclohexylacetic acid
• 英文别名: (2S)-2-cyclohexyl-2-(phenylmethoxycarbonylamino)acetic acid
• CAS: 69901-75-3
• 化学式: C₁₆H₂₁NO₄
• 分子量: 291.347
• InChiKey: CUSYTUPJAYLNFQ-AWEZNQCLSA-N

物化性质

• 熔点：
  111-114°C
• 沸点：
  492.1±38.0 °C(Predicted)
• 密度：
  1.200±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于氯仿（少许）、DMSO（少许）、甲醇（少许）
• LogP：
  1.7 at 25℃ and pH2.5

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  21
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  75.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2924299090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: Z-Chg-OH
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: Z-Chg-OH
CAS number: 69901-75-3

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C16H21NO4
Molecular weight: 291.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  Cbz-环己基-L-甘氨酸 在 lithium aluminium tetrahydride 、 三氧化硫吡啶 、 N,N-二异丙基乙胺 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 为溶剂， 生成 ((S)-1-Cyclohexyl-2-oxo-ethyl)-carbamic acid benzyl ester
  参考文献：
  名称：

  Stereoselective silver triflate-mediated iodocyclization of carbamates

  摘要：

  Iodocyclization of carbamates involving electron-deficient olefins, (i.e. alpha,beta-unsaturated esters) is greatly facilitated by the use of silver(I) triflate and proceeds with excellent trans ring stereoselectivity. During this process, the resultant iodides can undergo epimerization, the rate of which is solvent-dependent.

  DOI：

  10.1016/s0040-4039(00)74232-8
• 作为产物：
  描述：

  2-环己基-2-氧代乙酸 在 [ruthenium(II)(η⁶-1-methyl-4-isopropyl-benzene)(chloride)(μ-chloride)]₂ 甲烷磺酸 、 (R)-(-)-[(S)-2-(diphenylphosphino)ferrocenyl]ethyldi-tert-butylphosphine 、 氢气 、 三乙胺 作用下， 以 乙醇 、 1,2-二氯乙烷 、 甲苯 为溶剂， 25.0 ℃ 、620.53 kPa 条件下， 反应 26.0h， 生成 Cbz-环己基-L-甘氨酸
  参考文献：
  名称：

  Asymmetric Hydrogenation of N-Sulfonylated-α-dehydroamino Acids:  Toward the Synthesis of an Anthrax Lethal Factor Inhibitor

  摘要：

  [GRAPHIC]A novel and highly enantioselective Ru-catalyzed hydrogenation of N-sulfonylated-alpha-dehydroamino acids has been discovered and demonstrated in the synthesis of an anthrax lethal factor inhibitor (LFI). Herein, this methodology is used to prepare N-sulfonylated amino acids in up to 98% ee. This unprecedented hydrogenation uses a chiral Ru catalyst rather than Rh as typical for acylated dehydroamino acids and esters, and this work reports the first asymmetric hydrogenation of a tetrasubstituted dehydroamino acid derivative using a Ru catalyst.

  DOI：

  10.1021/ol050869s

文献信息

• [EN] IAP INHIBITORS<br/>[FR] INHIBITEURS DE PROTÉINES D'APOPTOSE
  申请人：TETRALOGIC PHARM CORP

  公开号：WO2010138666A1

  公开（公告）日：2010-12-02

  The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.

  本发明描述了化合物、其制备方法、含有它们的药物组合物，以及它们在治疗中的应用。
• Enhanced antimalarial activity of plasmepsin V inhibitors by modification of the P 2 position of PEXEL peptidomimetics
  作者：William Nguyen、Anthony N. Hodder、Richard Bestel de Lezongard、Peter E. Czabotar、Kate E. Jarman、Matthew T. O'Neill、Jennifer K. Thompson、Helene Jousset Sabroux、Alan F. Cowman、Justin A. Boddey、Brad E. Sleebs

  DOI：10.1016/j.ejmech.2018.05.022

  日期：2018.6

  Previously, development of transition state PEXEL mimetic inhibitors of plasmepsin V have primarily focused on demonstrating the importance of the P3 Arg and P1 Leu in binding affinity and selectivity. Here, we investigate the importance of the P2 position by incorporating both natural and non-natural amino acids into this position and show disubstituted beta-carbon amino acids convey the greatest potency

  纤溶酶V是一种天冬氨酰蛋白酶，在携带带有疟原虫输出元件（PEXEL）基序的蛋白质（RxLxQ / E / D）出口到受感染的宿主红细胞以及疟疾寄生虫的存活中起关键作用。以前，纤溶酶V的过渡态PEXEL模拟抑制剂的开发主要集中于证明P 3 Arg和P 1 Leu在结合亲和力和选择性方面的重要性。在这里，我们通过将天然和非天然氨基酸都掺入该位置来研究P 2位置的重要性，并表明双取代的β-碳氨基酸可发挥最大的效能。因此，我们在P中显示了带有环己基甘氨酸或苯基甘氨酸的类似物2位是最有效的纤溶酶V抑制剂，可破坏输出蛋白中PEXEL基序的加工，导致恶性疟原虫无性阶段寄生虫死亡。
• Tetrahydroimidazo[1,2‐ <i>a</i> ]pyrazine Derivatives: Synthesis and Evaluation as Gα _q ‐Protein Ligands
  作者：Jim Küppers、Tobias Benkel、Suvi Annala、Kenichi Kimura、Lisa Reinelt、Bernd K. Fleischmann、Evi Kostenis、Michael Gütschow

  DOI：10.1002/chem.202001446

  日期：2020.10

  The 5,6,7,8‐tetrahydroimidazo[1,2‐a]pyrazine derivative BIM‐46174 and its dimeric form BIM‐46187 (1) are heterocyclized dipeptides that belong to the very few cell‐permeable compounds known to preferentially silence Gαq proteins. To explore the chemical space of Gαq inhibitors of the BIM chemotype, a combinatorial approach was conducted towards a library of BIM molecules. This library was evaluated

  5,6,7,8-四氢咪唑并[1,2- a ]吡嗪衍生物 BIM-46174 及其二聚体形式 BIM-46187 ( 1 ) 是杂环化二肽，属于极少数已知优先沉默 Gα 的细胞渗透性化合物q蛋白。为了探索 BIM 化学型 Gα q抑制剂的化学空间，对 BIM 分子库进行了组合方法。该文库在基于第二信使的荧光测定中进行了评估，通过测定细胞内肌醇1-磷酸来分析 Gα q蛋白的活性。推导了结构-活性关系并获得了生物活性的结构要求，它们是（i）氧化还原反应性硫醇/二硫烷子结构，（ii）N-末端碱性氨基，（iii）环己基丙氨酸部分，和（iv）双环骨架。活性化合物表现出细胞毒性，对此原型抑制剂进行了详细研究1。该化合物以 Gα q/11独立的方式影响结构细胞骨架动力学。
• [EN] BIVALENT ANTAGONISTS OF INHIBITORS OF APOPTOSIS PROTEINS<br/>[FR] ANTAGONISTES BIVALENTS D'INHIBITEURS DE PROTÉINES D'APOPTOSE
  申请人：HEPAGENE THERAPEUTICS HK LTD

  公开号：WO2020206000A1

  公开（公告）日：2020-10-08

  The present technology is directed to compounds, compositions, and methods related to treatment of cancers and viral infections mediated by IAPs, e.g., compounds of Formula I (including Formulas IA, IB, IC, ID, IE, IF, and IG), a stereoisomer thereof, or a pharmaceutically acceptable salt of the compound or the stereoisomer of the compound. In particular, the present compounds and compositions may be used to treat IAP-mediated ovarian cancer and hepatitis B infection.

  目前的技术是针对由IAP介导的癌症和病毒感染的化合物、组合物和治疗方法，例如Formula I（包括Formula IA、IB、IC、ID、IE、IF和IG）、其立体异构体，或该化合物或其立体异构体的药用盐。具体来说，目前的化合物和组合物可用于治疗IAP介导的卵巢癌和乙型肝炎感染。
• [EN] IAP INHIBITORS<br/>[FR] INHIBITEURS IAP
  申请人：TETRALOGIC PHARM CORP

  公开号：WO2011068926A1

  公开（公告）日：2011-06-09

  The present invention describes compounds, processes for their preparation, pharmaceutical compositions containing them, and their use in therapy.

  本发明描述了化合物、其制备方法、含有它们的药物组合物，以及它们在治疗中的应用。